Sodium-glucose cotransporter-2 inhibitor contributed to better efficacy outcomes in overall HF patients and showed an inspiring breakthrough in the treatment of HFpEF.
Keyphrases
- heart failure
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- type diabetes
- acute heart failure
- meta analyses
- atrial fibrillation
- metabolic syndrome
- combination therapy
- adipose tissue
- cardiac resynchronization therapy
- case control